Here are some updates about multiple sclerosis therapies, testing, and diagnosis.
Canadians with relapsing-remitting multiple sclerosis (RRMS) can now receive Merck’s Mavenclad (cladribine tablets), now that Health Canada has approved Mavenclad as a therapy to reduce the frequency of MS exacerbations and delay disease progression.
Merck expects the drug to be commercially available by early January 2018 throughout Canada, which has the world’s highest MS rate.
Read full article: MS News Last Week: Mavenclad, Steroids, Blood Tests and Laquinimod
|Read Full Article: MS News Last Week: Mavenclad, Steroids, Blood Tests and Laquinimod|